Advertisement
Screener

COMPASS PATHWAYS PLC (CMPS) Graph

CMPS Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $29.18M; Operating expenses $52.37M; Income tax $331.00K; Net income -$253.79M.
  • 2026-03-31: Research and development $26.48M; Operating expenses $42.90M; Income tax -$11.00K; Net income $91.20M.
  • 2025-12-31: Research and development $29.91M*; Operating expenses $45.95M*; Income tax -$2.73M*; Net income -$75.78M*.
  • 2025-09-30: Research and development $27.32M; Operating expenses $40.54M; Income tax -$230.00K; Net income -$137.72M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$29.18M$52.37M$331.00K-$253.79M
2026-03-31$26.48M$42.90M-$11.00K$91.20M
2025-12-31$29.91M*$45.95M*-$2.73M*-$75.78M*
2025-09-30$27.32M$40.54M-$230.00K-$137.72M
2025-06-30$30.32M$42.93M$137.00K-$38.40M
2025-03-31$30.88M$49.62M$354.00K-$17.86M
2024-09-30$32.93M$47.90M$173.00K-$38.50M
2024-06-30$29.07M$43.32M$176.00K-$38.10M
2024-03-31$24.90M$38.57M$222.00K-$35.19M
2023-09-30$21.53M$34.06M$62.00K-$33.39M
2023-06-30$19.82M$32.66M$194.00K-$28.34M
2023-03-31$19.04M$31.79M$130.00K-$24.21M
2022-09-30$13.98M$25.54M$120.00K-$18.37M
2022-06-30$15.92M$27.26M$56.00K-$21.04M
2022-03-31$15.36M$25.42M$140.00K-$21.17M
2021-09-30$12.20M$21.77M$63.00K-$15.85M
2021-06-30$11.35M$19.53M$9.00K-$17.53M
2021-03-31$6.88M$13.60M$28.00K-$12.71M
2020-09-30$6.88M$13.48M$82.00K-$15.85M
2020-06-30$6.72M$17.69M$43.00K-$17.53M
2020-03-31(m)(m)(m)-$8.59M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$55.66M$95.28M$320.00K-$162.59M
2025-06-30$61.20M$92.55M$491.00K-$56.27M
2024-06-30$53.97M$81.89M$398.00K-$73.29M
2023-06-30$38.85M$64.45M$324.00K-$52.54M
2022-06-30$31.28M$52.68M$196.00K-$42.21M
2021-06-30$18.24M$33.13M$37.00K-$30.24M
2020-06-30$11.95M$26.39M$43.00K-$24.83M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-09-30$88.53M$133.09M$261.00K-$193.98M
2024-09-30$86.90M$129.79M$571.00K-$111.79M
2023-09-30$60.38M$98.51M$386.00K-$85.93M
2022-09-30$45.26M$78.21M$316.00K-$60.58M
2021-09-30$30.43M$54.90M$100.00K-$46.09M
2020-09-30$18.82M$39.87M$125.00K-$41.53M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$118.44M$179.04M-$2.47M-$269.77M
2024-12-31$119.04M$178.21M$1.59M-$155.12M
2023-12-31$87.52M$136.92M$780.00K-$118.46M
2022-12-31$65.05M$110.40M$408.00K-$91.50M
2021-12-31$44.03M$83.22M$199.00K-$71.74M
2020-12-31$23.37M$51.39M$32.00K-$60.33M
2019-12-31$12.56M$21.18M$15.00K-$19.61M

Similar stocks

Stock NameCountryMarket CapPE Ratio
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77
Septerna, Inc. (SEPN)United States$1.783B-63.01
Xencor Inc (XNCR)United States$1.776B-7.33
Zymeworks Inc. (ZYME)United States$1.902B-12.44
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
Biohaven Ltd. (BHVN)United States$1.990B-3.83
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82